Digoxin tablets

1. Positive inotropic effect: This product selectively binds to the Na--K ATPase of the myocardial cell membrane and inhibits the activity of the enzyme, which impairs the active coupled transport of Na-K inside and outside the myocardial cell membrane, increases the concentration of Na in myocardial cells, and thus makes the NaCa2 exchange on the sarcolemma more active, increases the amount of Ca2 in the cytoplasm, and increases the Ca2 reserve in the sarcoplasmic reticulum. When the myocardium is excited, more Ca2 is released; the increase in the concentration of Ca2 in myocardial cells excites myocardial contractile proteins, thereby increasing myocardial contractility. 2. Negative frequency effect: Due to its positive inotropic effect, it increases the cardiac output of the failing heart, improves the hemodynamic state, eliminates the reflex increase of sympathetic nerve tension, and enhances the vagus nerve tension.

The chemical name of this product is: 3β-［［O-2, O-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-O-2, 6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-2, 6-dideoxy-β-D-ribo-hexopyranosyloxy］-12β, 14β-dihydroxy-5β-cardiosteroid-20(22)ene lactone.

This product is white tablets.

1. Used for acute and chronic heart failure such as hypertension, valvular heart disease, congenital heart disease, etc. It is especially suitable for heart failure with atrial fibrillation accompanied by rapid ventricular rate; it has poor efficacy for heart failure caused by cor pulmonale, severe myocardial ischemia, active myocarditis and extracardiac factors such as severe anemia, hypothyroidism and vitamin B1 deficiency; 2. Used to control the ventricular rate and supraventricular tachycardia of patients with atrial fibrillation and atrial flutter accompanied by rapid ventricular rate.

Common oral dose for adults: 0.125~0.5mg, once a day, steady-state blood concentration can be reached in 7 days; if the rapid loading dose is reached, 0.25mg can be administered every 6~8 hours, with a total dose of 0.75~1.25mg/day; maintenance dose, 0.125~0.5mg once a day. Common oral dose for children: total amount of this product, premature infants 0.02~0.03mg/kg; newborns under 1 month old 0.03~0.04mg/kg; 1 month to 2 years old, 0.05~0.06mg/kg; 2~5 years old, 0.03~0.04mg/kg; 5~10 years old, 0.02~0.035/kg; 10 years old or above, according to the common adult dose; total amount of this product is divided into 3 times or given every 6~8 hours. The maintenance dose is 1/5~1/3 of the total dose

1 Common adverse reactions include: proarrhythmic effects, poor appetite or nausea, vomiting (stimulation of the medullary center), lower abdominal pain, abnormal weakness, and tenderness. 2 Rare reactions include: blurred vision or color vision, such as yellow vision, green vision, diarrhea, and central nervous system reactions such as depression or confusion. 3 Rare reactions include: drowsiness, headache and rash, urticaria (allergic reaction). 4 Among the manifestations of digitalis poisoning, proarrhythmia is the most important, and the most common is ventricular premature beats, which account for about 33% of proarrhythmic adverse reactions. The second most common reactions are atrioventricular block, paroxysmal or accelerated junctional tachycardia, paroxysmal atrial tachycardia with atrioventricular block, and ventricular

1. Combined with calcium injection; 2. Poisoning by any digitalis preparation; 3. Ventricular tachycardia, ventricular fibrillation; 4. Obstructive hypertrophic cardiomyopathy (can still be considered if accompanied by systolic dysfunction or atrial fibrillation); 5. Preexcitation syndrome with atrial fibrillation or flutter.

Precautions for children: 1. Children's tolerance to this product is uncertain, and their renal clearance is reduced; 2. Children and immature children are sensitive to this product, and the dosage should be reduced according to their degree of immaturity. In terms of body weight or body surface area, the dosage for infants over 1 month old is slightly larger than that for adults. Precautions for pregnancy and lactation: This product can pass through the placenta, so the maternal dosage may increase in the late pregnancy, and the dosage must be reduced 6 weeks after delivery. This product can be excreted into breast milk, and lactating women must weigh the pros and cons when using it. Precautions for the elderly: Elderly people with impaired liver and kidney function, reduced apparent distribution volume, or electrolyte imbalance have low tolerance to this product and must reduce the dosage.

1. When used together with amphotericin B, corticosteroids or potassium-losing diuretics such as bumetanide (the product is buturamine) and ethacrynic acid (ethacrynic acid), it can cause hypokalemia and lead to digitalis poisoning. 2. When used together with antacids (especially magnesium trisilicate) or antidiarrheal adsorbents such as white clay, pectin, colestyramine (cholestyramine) and other anion exchange resins, sulfasalazine or neomycin, and para-aminosalicylic acid, it can inhibit the absorption of digitalis cardiac glycosides and lead to a weakening of the effect of cardiac glycosides. 3. When used together with antiarrhythmic drugs, calcium salt injections, cocaine, pancuronium bromide, etc.

Keep sealed.

0.25mg

36 months

Shanghai Yurui BIOTECHNOLOGY (Anyang) Pharmaceutical Co., Ltd.

• Founded in:

  2005-04-18

• Address:

  Anyang Hanling Industrial Park

• Tax NO.:

  914105227880639115

• Registered Funds:

  81.66 million yuan

• Website:

  Log in to view

• Email:

  Log in to view